AIMS: Selisistat, a selective SirT1 inhibitor is being developed as a potentially disease-modifying therapeutic for Huntington's disease (HD). This was the first study of selisistat in HD patients and was primarily aimed at development of pharmacodynamic biomarkers. METHODS: This was a randomized, double-blind, placebo-controlled, multicentre exploratory study. Fifty-five male and female patients in early stage HD were randomized to receive 10 mg or 100 mg of selisistat or placebo once daily for 14 days. Blood sampling, clinical and safety assessments were conducted throughout the study. Candidate pharmacodynamic markers included circulating soluble huntingtin and innate immune markers. RESULTS: Selisistat was found to be safe and well tolerated, and systemic exposure parameters showed that the average steady-state plasma concentration achieved at the 10 mg dose level (125 nm) was comparable with the IC50 for SirT1 inhibition. No adverse effects on motor, cognitive or functional readouts were recorded. While circulating levels of soluble huntingtin were not affected by selisistat in this study, the biological samples collected have allowed development of assay technology for use in future studies. No effects on innate immune markers were seen. CONCLUSIONS: Selisistat was found to be safe and well tolerated in early stage HD patients at plasma concentrations within the anticipated therapeutic concentration range.
RCT Entities:
AIMS: Selisistat, a selective SirT1 inhibitor is being developed as a potentially disease-modifying therapeutic for Huntington's disease (HD). This was the first study of selisistat in HDpatients and was primarily aimed at development of pharmacodynamic biomarkers. METHODS: This was a randomized, double-blind, placebo-controlled, multicentre exploratory study. Fifty-five male and female patients in early stage HD were randomized to receive 10 mg or 100 mg of selisistat or placebo once daily for 14 days. Blood sampling, clinical and safety assessments were conducted throughout the study. Candidate pharmacodynamic markers included circulating soluble huntingtin and innate immune markers. RESULTS:Selisistat was found to be safe and well tolerated, and systemic exposure parameters showed that the average steady-state plasma concentration achieved at the 10 mg dose level (125 nm) was comparable with the IC50 for SirT1 inhibition. No adverse effects on motor, cognitive or functional readouts were recorded. While circulating levels of soluble huntingtin were not affected by selisistat in this study, the biological samples collected have allowed development of assay technology for use in future studies. No effects on innate immune markers were seen. CONCLUSIONS:Selisistat was found to be safe and well tolerated in early stage HDpatients at plasma concentrations within the anticipated therapeutic concentration range.
Authors: Sarah J Tabrizi; Ralf Reilmann; Raymund A C Roos; Alexandra Durr; Blair Leavitt; Gail Owen; Rebecca Jones; Hans Johnson; David Craufurd; Stephen L Hicks; Christopher Kennard; Bernhard Landwehrmeyer; Julie C Stout; Beth Borowsky; Rachael I Scahill; Chris Frost; Douglas R Langbehn Journal: Lancet Neurol Date: 2011-12-02 Impact factor: 44.182
Authors: Giorgio Ramadori; Charlotte E Lee; Angie L Bookout; Syann Lee; Kevin W Williams; Jason Anderson; Joel K Elmquist; Roberto Coppari Journal: J Neurosci Date: 2008-10-01 Impact factor: 6.167
Authors: Hyunkyung Jeong; Florian Then; Thomas J Melia; Joseph R Mazzulli; Libin Cui; Jeffrey N Savas; Cindy Voisine; Paolo Paganetti; Naoko Tanese; Anne C Hart; Ai Yamamoto; Dimitri Krainc Journal: Cell Date: 2009-04-03 Impact factor: 41.582
Authors: Michael Orth; Olivia J Handley; Carsten Schwenke; Stephen B Dunnett; David Craufurd; Aileen K Ho; Edward Wild; Sarah J Tabrizi; G Bernhard Landwehrmeyer Journal: PLoS Curr Date: 2010-09-28
Authors: J S Paulsen; D R Langbehn; J C Stout; E Aylward; C A Ross; M Nance; M Guttman; S Johnson; M MacDonald; L J Beglinger; K Duff; E Kayson; K Biglan; I Shoulson; D Oakes; M Hayden Journal: J Neurol Neurosurg Psychiatry Date: 2007-12-20 Impact factor: 10.154
Authors: Robin Bonomi; Vadim Popov; Maxwell T Laws; David Gelovani; Anjoy Majhi; Aleksandr Shavrin; Xin Lu; Otto Muzik; Nashaat Turkman; Renshyan Liu; Thomas Mangner; Juri G Gelovani Journal: J Med Chem Date: 2018-08-13 Impact factor: 7.446
Authors: Gary P Brennan; Deblina Dey; Yuncai Chen; Katelin P Patterson; Eric J Magnetta; Alicia M Hall; Celine M Dube; Yu-Tang Mei; Tallie Z Baram Journal: Cell Rep Date: 2016-03-03 Impact factor: 9.423